Related content

Use of Systemic Antineoplastic Drug Therapy after Regulatory Agency Approval

By  

Oncology, Vol. 72, Iss. 3-4, 2007-12 ,pp. : 145-146

Karger

Access to resources Recommend Favorite

Is It Time to Inform This Patient that Further Antineoplastic Drug Therapy Will Not Be of Clinical Value?

By  

Case Reports in Oncology, Vol. 3, Iss. 1, 2010-03 ,pp. : 59-62

Karger

Access to resources Recommend Favorite

Effects of Anti-neoplastic Agents on the Recovery of Bacteria and Yeasts in an Automated Blood Culture System

By Kinnunen Urpo   Koistinen Pirjo   Syrjälä Hannu   Koskela Markku  

Scandinavian Journal of Infectious Diseases, Vol. 32, Iss. 1, 2000-02 ,pp. : 63-67

Informa Healthcare

Access to resources Recommend Favorite

Withholding Recognized Effective Adjuvant Anti-Neoplastic Chemotherapy in a Setting with Known Highly Active Treatment for Recurrent Disease: A Case Report

By  

Case Reports in Oncology, Vol. 3, Iss. 2, 2010-07 ,pp. : 231-233

Karger

Access to resources Recommend Favorite

Proposal to Rigorously Evaluate the Clinical Benefits Associated with a Novel Anti-Neoplastic Strategy outside the Confines of a Randomized Trial

By  

Oncology, Vol. 79, Iss. 5-6, 2011-03 ,pp. : 321-323

Karger

Access to resources Recommend Favorite